Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Unapproved injectable exosomes are landing patients in dermatology offices with stubborn facial granulomas. A case presented at the American Society for Dermatologic Surgery Annual Meeting highlighted a 54-year-old woman who developed firm, itchy skin lesions after receiving exosome injections at an unlicensed facility. With no FDA-approved exosome products on the market, dermatologists are urging patients to steer clear entirely.
Exosomes — extracellular vesicles popular in South Korea for their perceived skin rejuvenation benefits — are gaining traction in the U.S., but without FDA approval and with serious risks attached. At the American Society for Dermatologic Surgery Annual Meeting, Dr. Lauren S. Mohan presented a cautionary case: a 54-year-old woman who developed firm, itchy pink papules on her forehead, temples, and under-eye areas weeks after receiving exosome injections at an unlicensed facility.
Biopsy confirmed granulomatous inflammation, and the source of the injected material was completely unknown — making treatment a guessing game. Mohan and her team tried intralesional corticosteroids and laser therapy with minimal success, eventually turning to a combination of 5-fluorouracil, corticosteroids, and colchicine based on limited case report evidence.
Key Takeaways:
Why it matters: With no FDA-approved exosome injectables on the market and products potentially sourced from unregulated settings, patients face unpredictable and difficult-to-treat complications. Clinicians should proactively counsel patients against seeking these treatments at unlicensed facilities or abroad.